Macrolide Antibiotics Market Share

Global Macrolide Antibiotics Market Overview

Macrolide Antibiotics Market Size was valued at USD 50.9 Billion in 2022. The Macrolide Antibiotics market industry is projected to grow from USD 57.57 Billion in 2023 to USD 154.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.10% during the forecast period (2023 - 2032). Rising rates of skin infections, rising need for medications to treat bacterial skin infections, and quick growth of antibiotics, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Macrolide Antibiotics Market Trends

• Growing demand for drugs against bacterial infection is driving the market growth

A well-known class of antimicrobial drugs known as macrolide antibiotics has been used extensively in the treatment of bacterial infections and other disorders. Sales of macrolides agents help in the battle against various bacterial infections as a result of the rising rates of bacterial infection around the world and rising macrolide demand. The development of multidrug-resistant bacterial strains and the additional benefits of macrolide sales over traditional antibiotics have both led to the discovery that macrolides are more efficient. The sales of macrolides in the current market are influenced by this factor.

A shorter period of patent exclusivity for new drug applications in the pharmaceutical industry as a result of reduced government involvement in the approval of patents in the drug or pharmaceutical sector also increased the sales of macrolides in a number of regions around the world. It has been found that people today are more concerned about their health and protective of it than they were in the past. The sales of macrolides in both developed and developing regions are influenced by the growing patient awareness, health consciousness, and medical spending. As a result, occasionally, consumers' livers may be injured as a result of overdosing or using expired macrolides. This side effect may negatively affect macrolide sales, which could limit demand for macrolides throughout the anticipated period. Although this is a minor problem, manufacturers can handle it by increasing consumer awareness and teaching them about the expiration date and the bad effects of using expired macrolides. By doing this, we can help firms increase the market share for macrolides while minimising negative effects. Thus, driving the Macrolide Antibiotics market revenue.

Macrolide Antibiotics Market Segment Insights

Macrolide Antibiotics Drug Insights

The Macrolide Antibiotics Market segmentation, based on drugs includes Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin. With 25% of market revenue (18.48 billion) coming from the azithromycin category, the market was dominated by this product. due to the fact that it has broad-spectrum effectiveness against a variety of bacteria, including both Gram-positive and Gram-negative species. It can therefore be used as an antibiotic to treat infections brought on by a variety of bacteria.

Macrolide Antibiotics Route of Administration Insights

The Macrolide Antibiotics Market segmentation, based on Route of Administration, includes Oral and Parenteral. The highest share was made by oral category (65.4%). Convenience, affordability, high patient compliance, and ease of administration are boosting the market's segment growth.

Macrolide Antibiotics Indication Insights

The Macrolide Antibiotics Market segmentation, based on Indication, includes Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, and Others. The category with the highest revenue was cerebral toxoplasmosis (35.4%). Within 10 to 14 days of therapy, clinical and radiological improvement is typically observed, and this is the main driver fueling the market's segmental expansion.

Macrolide End User Insights

The Macrolide Antibiotics Market segmentation, based on End User, includes Hospitals, Dermatology Clinics, Pharmaceutical Companies, and Others. Due to the widespread use of macrolides for the treatment of hospital acquired infections, the hospital category produced the largest revenue (41.4%). Growing numbers of elderly people who are susceptible to various ailments raise the need for medical services, which drives up healthcare costs and raises demand for goods.

Figure 1: Macrolide Antibiotics Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Macrolide Antibiotics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Macrolide Antibiotics Market dominated this market in 2022 (45.80%). This is due to elements including the region's high demand for and usage of antibiotics, particularly macrolides. The second most often prescribed antibiotic class in the US is the macrolide family, yet incorrect medication is rife, according to research on outpatient macrolide antibiotic prescribing in the US. Further, the U.S. Macrolide Antibiotics market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: MACROLIDE ANTIBIOTICS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Macrolide Antibiotics market accounts for the second-largest market share. This is because the demand for antibiotics is rising as the prevalence of infectious diseases rises. Further, the German Macrolide Antibiotics market held the largest market share, and the UK Macrolide Antibiotics market was the fastest growing market in the European region

The Asia-Pacific Macrolide Antibiotics Market is expected to grow at the fastest CAGR from 2023 to 2032. The increasing the amount spent on healthcare and raising awareness of the availability of these treatments. Additionally, it is projected that Japan's favourable reimbursement regulations may increase the sales of macrolide antibiotics there. Moreover, China’s Macrolide Antibiotics market held the largest market share, and the Indian Macrolide Antibiotics market was the fastest growing market in the Asia-Pacific region.

Macrolide Antibiotics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Macrolide Antibiotics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Macrolide Antibiotics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Macrolide Antibiotics industry to benefit clients and increase the market sector. In recent years, the Macrolide Antibiotics industry has offered some of the most significant advantages to medicine. Major players in the Macrolide Antibiotics market, including Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.), WOCKHARDT (U.S.), and Others are attempting to increase market demand by investing in research and development operations.

One of Merck & Co., Inc.'s subsidiaries is Merck Sharp & Dohme Corp. It is a large healthcare organisation that offers cutting-edge medical treatments. MSD is another name for Merck Sharp & Dohme Corp. outside of North America and Canada. One of the biggest pharmaceutical businesses in the world is this one. The company Merck Sharp & Dohme Corp. finds, develops, and provides drugs, vaccines, and healthcare items for both humans and animals. The post hoc analysis of three phase 2/3 trials on the immunogenicity of the rVSV-G-ZEBOV-GP Ebola vaccine is one of the studies that Merck Sharp & Dohme Corp. has participated in. The autoinjector pen is one of the medical devices that Merck Sharp & Dohme Corp. has created. Customers, including individuals and businesses, can choose from a range of banking services provided by Merck Sharp & Dohme Corp. Federal Credit Union.

Pfizer Inc. is a biopharmaceutical firm with a research-based foundation that discovers, develops, produces, markets, distributes, and sells biopharmaceutical goods globally. Charles Pfizer and his relative Charles F. Erhart, two German businessmen, established Pfizer in New York in 1849. At The Spiral in Manhattan, New York City, Pfizer has its main office. Pfizer provides drugs and vaccines for a range of medical conditions, including oncology, rare illnesses, internal medicine, vaccinations, inflammation and immunology, and consumer healthcare.

Key Companies in the Macrolide Antibiotics market include

• Merck Sharp & Dohme Corp (U.S.)


• Pfizer Inc. (U.S.)


• Neo Química (Brazil)


• Macrolide Pharmaceuticals (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Fresenius Kabi USA (U.S.)


• Sandoz International GmbH (Germany)


• Gland Pharma Limited (India)


• Mylan N.V. (U.S.)


• WOCKHARDT (U.S.)

Macrolide Antibiotics Industry Developments

April 2021: Amplyx Pharmaceuticals and its anti-fungal drug fosmanogepix were bought by Pfizer.

February 2021: In order to maintain its position as the industry leader in antibiotics, Sandoz inked a contract to buy GSK's cephalosporin division. The partnership demonstrates Sandoz's dedication to expanding its antibiotics business.

Macrolide Antibiotics Market Segmentation

Macrolide Antibiotics Drugs Outlook

• Azithromycin


• Clarithromycin


• Erythromycin


• Fidaxomicin


• Telithromycin

Macrolide Antibiotics Route of Administration Outlook

• Oral


• Parenteral

Macrolide Antibiotics Indication Outlook

• Infection Due to Mycoplasma Pneumoniae


• Legionella Sp, or Bordetella Pertussis


• Symptomatic Cat-Scratch Disease


• Bacillary Angiomatosis


• Peliosis Hepatis in Patients with AIDS


• Cerebral Toxoplasmosis: Clinical and radiological improvement is usually seen within 10 to 14 days of therapy.


• Uncomplicated Skin Infections


• Others

Macrolide Antibiotics End User Outlook

• Hospitals


• Dermatology Clinics


• Pharmaceutical Companies


• Others

Macrolide Antibiotics Regional Outlook

• North America
  
  
  
  • US.
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America